Carbamic Acid

Carbamic Acid

SCHEMBL4877013

CC(=O)Nc1nc(CCc2ccc(NC=NC(=O)O)cc2)c(C(=O)NCc2cccnc2)s1.NC(=O)O

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
HTT P42858 2/20 0.46
AOC3 Q16853 2/20 0.43
HPGD P15428 4/20 0.39
POLB P06746 3/20 0.39
HSD17B10 Q99714 3/20 0.39
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
DUSP3 P51452 1/20 0.39
CHRM4 P08173 1/20 0.39
RAB9A P51151 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
SCD O00767 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbamic Acid SCHEMBL4992521 0.93 AOC3 (0.48) AOC3POLBRAB9ASCDMEN1
Carbamic Acid SCHEMBL4873592 0.91 AOC3 (0.41) AOC3SCD
Carbamic Acid SCHEMBL4988460 0.90 KMT2A (0.43) ALDH1A1HTTAOC3HPGDRAB9A
Carbamic Acid SCHEMBL4873054 0.88 AOC3 (0.43) AOC3SCD
Carbamic Acid SCHEMBL4876510 0.86 AOC3 (0.44) AOC3POLBRAB9AMAPTSCD
Carbamic Acid SCHEMBL5670031 0.86 AOC3 (0.43) AOC3
Carbamic Acid SCHEMBL4876807 0.86 PPARA (0.42) AOC3CHRM4
Carbamic Acid SCHEMBL4874057 0.86 AOC3 (0.51) AOC3CHRM4
SCHEMBL14019587 0.85 ALDH1A1 (0.52) ALDH1A1HTTAOC3HPGDPOLB
Carbamic Acid SCHEMBL4873455 0.85 PPARA (0.40) AOC3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1608365-B1 METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE R TECH UENO LTD (JP) 2013-10-02 EP disclosed
US-7442715-B2 Thiazole derivatives ASTELLAS PHARMA INC. (JP) 2008-10-28 US disclosed
US-20060276521-A1 Thiazole derivatives ASTELLAS PHARMA INC. (JP) 2006-12-07 US disclosed
US-7125901-B2 Thiazole derivatives ASTELLAS PHARMA INC. (JP) 2006-10-24 US disclosed
US-20060128770-A1 Thiazole derivatives FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276521-A1 Thiazole derivatives VCAM1, ICAM1, TXNL1 ALDH1A1 930/4885HTT 990/4885AOC3 782/4885
US-20060128770-A1 Thiazole derivatives VCAM1, ICAM1, TXNL1 ALDH1A1 930/4885HTT 990/4885AOC3 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.